NASDAQ · TPST
Healthcare · Biotechnology
$0.79
Down-$0.01 (-0.64%)
Updated Oct 6, 2026, 11:43 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TPST
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
TPST closed at $0.79 after 20 trading sessions, down 19.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $0.80 | $0.825 | $0.782 | $0.7926 | 156.52K |
| Oct 2, 2026 | $0.8239 | $0.85 | $0.78 | $0.8112 | 2.27M |
| Oct 1, 2026 | $0.81 | $0.8296 | $0.8001 | $0.8061 | 153.41K |
| Sep 30, 2026 | $0.805 | $0.84 | $0.80 | $0.8343 | 266.1K |
| Sep 29, 2026 | $0.8256 | $0.8513 | $0.8035 | $0.8103 | 154.63K |
| Sep 28, 2026 | $0.825 | $0.8488 | $0.80 | $0.8316 | 259.05K |
| Sep 25, 2026 | $0.8677 | $0.8946 | $0.815 | $0.829 | 288.32K |
| Sep 24, 2026 | $0.9012 | $0.9192 | $0.85 | $0.85 | 447.18K |
| Sep 23, 2026 | $0.989 | $1.01 | $0.899 | $0.922 | 791.84K |
| Sep 22, 2026 | $0.78 | $1.09 | $0.7704 | $1.00 | 3.61M |
| Sep 21, 2026 | $0.92 | $0.9449 | $0.7653 | $0.7738 | 1.9M |
| Sep 18, 2026 | $0.84 | $1.09 | $0.84 | $0.968 | 4.8M |
| Sep 17, 2026 | $1.08 | $1.08 | $0.85 | $0.895 | 7.87M |
| Sep 16, 2026 | $1.07 | $1.48 | $0.9674 | $1.21 | 104.6M |
| Sep 15, 2026 | $0.799 | $0.8094 | $0.7432 | $0.7554 | 26.44M |
| Sep 14, 2026 | $0.80 | $0.8221 | $0.7522 | $0.7843 | 143.42K |
| Sep 11, 2026 | $0.79 | $0.8872 | $0.7583 | $0.8117 | 783.63K |
| Sep 10, 2026 | $0.95 | $0.95 | $0.80 | $0.8026 | 391.01K |
| Sep 9, 2026 | $0.985 | $0.99 | $0.9088 | $0.9089 | 189.5K |
| Sep 8, 2026 | $1.02 | $1.03 | $0.976 | $0.9872 | 199.94K |
The latest Smart Investors Daily articles mentioning TPST.
Company
Market Activity
Research & News
TPST research
Company profile and research snapshot.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 10, 2025 | Scotiabank | Sector Perform | — |
| Apr 10, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 28, 2025 | Scotiabank | Sector Outperform | — |
No generated briefing is available yet.
Benzinga · Sep 25, 2026
Up to 9,534,164 Shares of Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus, referred to as the selling stockholders, of up to 9,534,164
Benzinga · Sep 24, 2026
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
Yahoo · Sep 23, 2026
Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companiesBRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the
Yahoo · Sep 11, 2026
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrantsBRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TPST.
